CTLA4 and neoplasm: For example, it could be proposed to conduct a new randomized trial in the setting of recurrent GB, comparing the standard of care (lomustine) with the combination of DCVax-L plus an immune checkpoint inhibitor (PD-1/PD-L1 blocker or CTLA-4 inhibitor) as a strategy for boosting anti-tumor immune responses [28].